Nissay Asset Management Corp Japan ADV Has $26.75 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Nissay Asset Management Corp Japan ADV grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 284,243 shares of the biopharmaceutical company's stock after acquiring an additional 14,009 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in Gilead Sciences were worth $26,750,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC lifted its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 25,429 shares of company stock valued at $2,894,445. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Gilead Sciences stock traded up $2.16 during trading hours on Friday, hitting $102.50. 6,395,303 shares of the stock were exchanged, compared to its average volume of 7,661,033. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a market capitalization of $127.63 billion, a P/E ratio of 277.03, a P/E/G ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The business's 50-day moving average is $105.75 and its two-hundred day moving average is $99.68.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the prior year, the firm earned ($1.32) earnings per share. Gilead Sciences's revenue was down .3% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.08%. Gilead Sciences's payout ratio is presently 66.53%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GILD. Piper Sandler lifted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Oppenheimer reduced their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.